BidaskClub upgraded shares of Icon (NASDAQ:ICLR) from a sell rating to a hold rating in a report published on Friday morning.
ICLR has been the topic of a number of other research reports. KeyCorp restated a buy rating and issued a $130.00 price target on shares of Icon in a report on Thursday, January 11th. Zacks Investment Research upgraded Icon from a hold rating to a buy rating and set a $127.00 price target on the stock in a report on Wednesday, December 27th. SunTrust Banks restated a buy rating and issued a $133.00 price target on shares of Icon in a report on Monday, January 22nd. ValuEngine upgraded Icon from a hold rating to a buy rating in a report on Sunday, December 31st. Finally, Credit Suisse Group upgraded Icon to a buy rating and set a $131.00 target price on the stock in a report on Friday, February 16th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Icon currently has a consensus rating of Buy and a consensus price target of $126.00.
Shares of Icon (NASDAQ ICLR) opened at $123.90 on Friday. The firm has a market capitalization of $6,700.00, a P/E ratio of 23.47, a P/E/G ratio of 1.73 and a beta of 0.45. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.29. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.65.
Large investors have recently made changes to their positions in the business. Insight Capital Research & Management Inc. acquired a new stake in Icon during the 3rd quarter valued at $1,359,000. BT Investment Management Ltd acquired a new stake in Icon during the 3rd quarter valued at $325,000. JPMorgan Chase & Co. boosted its holdings in shares of Icon by 11.5% during the third quarter. JPMorgan Chase & Co. now owns 42,043 shares of the medical research company’s stock worth $4,697,000 after purchasing an additional 4,320 shares during the last quarter. NorthCoast Asset Management LLC boosted its holdings in shares of Icon by 23.4% during the third quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 3,419 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. boosted its holdings in shares of Icon by 2.4% during the fourth quarter. Farmers & Merchants Investments Inc. now owns 47,502 shares of the medical research company’s stock worth $5,327,000 after purchasing an additional 1,110 shares during the last quarter. Hedge funds and other institutional investors own 90.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Icon (ICLR) to Hold” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/03/13/bidaskclub-upgrades-icon-iclr-to-hold.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.